Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. more
Time Frame | SLDB | Sector | S&P500 |
---|---|---|---|
1-Week Return | -15.27% | -2.12% | -3% |
1-Month Return | -16.13% | -3.42% | -0.73% |
3-Month Return | -47.07% | -11.13% | 2.87% |
6-Month Return | -33.97% | -5.74% | 7.17% |
1-Year Return | -15.79% | 3.97% | 25.31% |
3-Year Return | -85.85% | 1.05% | 28.38% |
5-Year Return | -93.24% | 34.37% | 81.89% |
10-Year Return | -98.77% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 3.33M | 13.62M | 8.09M | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":24.49,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.43,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 2.82M | 3.92M | 58.74M | 2.41M | 76.56M | [{"date":"2019-12-31","value":3.69,"profit":true},{"date":"2020-12-31","value":5.12,"profit":true},{"date":"2021-12-31","value":76.72,"profit":true},{"date":"2022-12-31","value":3.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (2.82M) | (3.92M) | (45.12M) | 5.69M | (76.56M) | [{"date":"2019-12-31","value":-49.67,"profit":false},{"date":"2020-12-31","value":-68.98,"profit":false},{"date":"2021-12-31","value":-793.51,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1346.52,"profit":false}] |
Gross Margin | (Infinity%) | (117.60%) | (331.27%) | 70.25% | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":-167.4,"profit":false},{"date":"2021-12-31","value":-471.56,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 119.32M | 86.46M | 85.87M | 107.37M | 104.31M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":72.46,"profit":true},{"date":"2021-12-31","value":71.97,"profit":true},{"date":"2022-12-31","value":89.98,"profit":true},{"date":"2023-12-31","value":87.43,"profit":true}] |
Operating Income | (119.32M) | (88.41M) | (72.25M) | (106.45M) | (104.31M) | [{"date":"2019-12-31","value":-11931800000,"profit":false},{"date":"2020-12-31","value":-8840600000,"profit":false},{"date":"2021-12-31","value":-7225400000,"profit":false},{"date":"2022-12-31","value":-10645200000,"profit":false},{"date":"2023-12-31","value":-10431500000,"profit":false}] |
Total Non-Operating Income/Expense | 3.67M | (1.71M) | 130.00K | 23.09M | 15.32M | [{"date":"2019-12-31","value":15.92,"profit":true},{"date":"2020-12-31","value":-7.42,"profit":false},{"date":"2021-12-31","value":0.56,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":66.34,"profit":true}] |
Pre-Tax Income | (117.22M) | (88.29M) | (72.19M) | (85.98M) | (96.02M) | [{"date":"2019-12-31","value":-11722300000,"profit":false},{"date":"2020-12-31","value":-8829000000,"profit":false},{"date":"2021-12-31","value":-7218800000,"profit":false},{"date":"2022-12-31","value":-8598100000,"profit":false},{"date":"2023-12-31","value":-9601500000,"profit":false}] |
Income Taxes | (1.58M) | 1.83M | (64.00K) | (20.47M) | - | [{"date":"2019-12-31","value":-86.43,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-3.5,"profit":false},{"date":"2022-12-31","value":-1119.86,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (115.64M) | (90.12M) | (72.12M) | (65.51M) | - | [{"date":"2019-12-31","value":-11564300000,"profit":false},{"date":"2020-12-31","value":-9011800000,"profit":false},{"date":"2021-12-31","value":-7212400000,"profit":false},{"date":"2022-12-31","value":-6551000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (117.22M) | (88.29M) | (72.19M) | (85.98M) | (90.83M) | [{"date":"2019-12-31","value":-11722300000,"profit":false},{"date":"2020-12-31","value":-8829000000,"profit":false},{"date":"2021-12-31","value":-7218800000,"profit":false},{"date":"2022-12-31","value":-8598100000,"profit":false},{"date":"2023-12-31","value":-9083000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (115.64M) | (90.12M) | (72.12M) | (65.51M) | (96.02M) | [{"date":"2019-12-31","value":-11564300000,"profit":false},{"date":"2020-12-31","value":-9011800000,"profit":false},{"date":"2021-12-31","value":-7212400000,"profit":false},{"date":"2022-12-31","value":-6551000000,"profit":false},{"date":"2023-12-31","value":-9601500000,"profit":false}] |
EPS (Diluted) | (43.95) | (24.75) | (10.20) | (9.99) | (4.80) | [{"date":"2019-12-31","value":-4395,"profit":false},{"date":"2020-12-31","value":-2475,"profit":false},{"date":"2021-12-31","value":-1020,"profit":false},{"date":"2022-12-31","value":-999,"profit":false},{"date":"2023-12-31","value":-480,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SLDB | |
---|---|
Cash Ratio | 7.49 |
Current Ratio | 7.85 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SLDB | |
---|---|
ROA (LTM) | -35.33% |
ROE (LTM) | -65.79% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SLDB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.21 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.79 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SLDB | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 3.65 |
P/B | 1.00 |
Price/FCF | NM |
EV/R | 1.16 |
EV/Ebitda | NM |
Solid Biosciences LLC (SLDB) share price today is $4.16
Yes, Indians can buy shares of Solid Biosciences LLC (SLDB) on Vested. To buy Solid Biosciences LLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SLDB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Solid Biosciences LLC (SLDB) via the Vested app. You can start investing in Solid Biosciences LLC (SLDB) with a minimum investment of $1.
You can invest in shares of Solid Biosciences LLC (SLDB) via Vested in three simple steps:
The 52-week high price of Solid Biosciences LLC (SLDB) is $15.05. The 52-week low price of Solid Biosciences LLC (SLDB) is $3.9.
The price-to-earnings (P/E) ratio of Solid Biosciences LLC (SLDB) is
The price-to-book (P/B) ratio of Solid Biosciences LLC (SLDB) is 1.00
The dividend yield of Solid Biosciences LLC (SLDB) is 0.00%
The market capitalization of Solid Biosciences LLC (SLDB) is $160.22M
The stock symbol (or ticker) of Solid Biosciences LLC is SLDB